Mechanisms of Antigen Trafficking in Autoimmunity
Mechanisms of Antigen Trafficking in Autoimmunity
批准号:
7352535
负责人:
Mark J Mamula
金额:
$4.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-17 至 2008-07-31
关键词:
Antigen-Presenting CellsAntigensAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune ResponsesAutoimmunityB-LymphocytesBiologicalCD4 Positive T LymphocytesCell physiologyComplexCore FacilityDataDendritic CellsDevelopmentDiseaseGoalsHumanImageImmune responseImmunityImmunizationKineticsLabelLaser MicroscopyLifeLocationLupusLupus ErythematosusLymphocyteModelingMonitorMusNucleosomesPathologyPatientsPeripheralProcessProductionProteinsResearch DesignSystemic Lupus ErythematosusT-Cell ActivationT-LymphocyteTimeWorkautoreactive B cellautoreactive T cellin vivointravital microscopylymph nodesmacrophageresponserituximabsuccesstraffickingtwo-photon
中文摘要
系统性红斑狼疮(SLE)是一种自身免疫性疾病,其特征是
英文摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of
autoantibodies to a select group of intracellular proteins, most notably, determinants on nucleosomes and
RNA-protein complexes. Autoimmune responses in human SLE and in murine models require the
processing and presentation of self antigen leading to the activation of T cells. CD4 T cells provide help to
autoreactive B cells, all leading to autoantibody production and pathology. The depletion of B cells in both
murine SLE and in Rituximab-treated patients ameliorates disease. Our previous studies have shown that
autoreactive B cells can escape peripheral tolerance, present autoantigens, and activate autoreactive T cells
from the normal repertoire of lymphocytes. Indeed, this may be one mechanism by which Rituximab therapy
is efficacious in human SLE. Our recent in vivo work demonstrates that unique subsets of antigen
presenting cells (APCs) activate T cells at different time points in the development of immunity. In particular,
B cells are the primary ARC in the early T cell responses post-immunization. Later in the autoimmune
response, B cells lose the ability to present antigen while dendritic cells (DCs) gradually acquire APC
function in T cell activation. Our studies demonstrate that DCs (and other APCs) can acquire antigen from
the B cells by an undetermined transfer mechanism. The major goal of this proposal is to directly follow the
transfer of antigen from antigen-specific B cells to other APCs and to determine if this mechanism has
biological significance to the onset of autoimmunity. The success of our work will depend on the use of the
In Vivo Imaging core facility. Our studies will examine the interaction of B cells, dendritic cells, and antigen T
cells within the lymph node of a living mouse by intravital microscopy. In particular, we will identify the
kinetics, location and mechanism of antigen transfer in vivo. Overall, our studies are designed to understand
the processing and presentation of presentation of autoantigens in murine models of lupus autoimmunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity
-
批准号:9909591
-
项目类别:
-
资助金额:$29.89万
-
财政年份:2019
-
负责人:Mark J Mamula
-
依托单位:
EGFR Peptides as Vaccines in Anti-Tumor Immunity
-
批准号:8647974
-
项目类别:
-
资助金额:$26.29万
-
财政年份:2013
-
负责人:Mark J Mamula
-
依托单位:
In Vito Imaging
-
批准号:7673607
-
项目类别:
-
资助金额:$19.92万
-
财政年份:2008
-
负责人:Mark J Mamula
-
依托单位:
Mechanisms of Antigen Trafficking in Autoimmunity
-
批准号:7680476
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2008
-
负责人:Mark J Mamula
-
依托单位:
EGFR Peptides as Vaccines in Anti-Tumor Immunity
-
批准号:7330500
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2007
-
负责人:Mark J Mamula
-
依托单位:
EGFR Peptides as Vaccines in Anti-Tumor Immunity
-
批准号:8150350
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2007
-
负责人:Mark J Mamula
-
依托单位:
In Vito Imaging
-
批准号:7352530
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2007
-
负责人:Mark J Mamula
-
依托单位:
EGFR Peptides as Vaccines in Anti-Tumor Immunity
-
批准号:8000852
-
项目类别:
-
资助金额:$62.87万
-
财政年份:2007
-
负责人:Mark J Mamula
-
依托单位:
Modified HER-2 Tumor Antigens for Vaccination in Cancer
-
批准号:6742316
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2004
-
负责人:Mark J Mamula
-
依托单位:
Modified HER-2 Tumor Antigens for Vaccination in Cancer
-
批准号:7288356
-
项目类别:
-
资助金额:$57.48万
-
财政年份:2004
-
负责人:Mark J Mamula
-
依托单位:
Modified HER-2 Tumor Antigens for Vaccination in Cancer
-
批准号:7158302
-
项目类别:
-
资助金额:$55.29万
-
财政年份:2004
-
负责人:Mark J Mamula
-
依托单位:
Isoaspartyl Modified Tumor Antigens for Vaccination
-
批准号:6840749
-
项目类别:
-
资助金额:$9.98万
-
财政年份:2004
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications and Autoimmunity
-
批准号:6337076
-
项目类别:
-
资助金额:$19.08万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications and Autoimmunity
-
批准号:6511529
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications and Autoimmunity
-
批准号:6877090
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications in Tolerance and Autoimmunity
-
批准号:7464321
-
项目类别:
-
资助金额:$41.34万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications in Tolerance and Autoimmunity
-
批准号:8240037
-
项目类别:
-
资助金额:$40.55万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications in Tolerance and Autoimmunity
-
批准号:8971933
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
Post Translational Modifications and Autoimmunity
-
批准号:6632440
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
ROLE OF SELF PEPTIDES IN TOLERANCE AND AUTOIMMUNITY
-
批准号:6484674
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2001
-
负责人:Mark J Mamula
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: